|
1
|
Balk SP and Knudsen KE: AR, the cell
cycle, and prostate cancer. Nucl Recept Signal.
6:E0012008.PubMed/NCBI
|
|
2
|
Lee JT, Lehmann BD, Terrian DM, et al:
Targeting prostate cancer based on signal transduction and cell
cycle pathways. Cell Cycle. 7:1745–1762. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Sawyers CL and Scher HI: Targeting
the androgen receptor pathway in prostate cancer. Curr Opin
Pharmacol. 8:440–448. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li J and Al-Azzawi F: Mechanism of
androgen receptor action. Maturitas. 63:142–148. 2009. View Article : Google Scholar
|
|
5
|
Arnold JT and Isaacs JT: Mechanisms
involved in the progression of androgen-independent prostate
cancers: it is not only the cancer cell’s fault. Endocr Relat
Cancer. 9:61–73. 2002.
|
|
6
|
Montgomery RB, Mostaghel EA, Vessella R,
et al: Maintenance of intratumoral androgens in metastatic prostate
cancer: a mechanism for castration-resistant tumor growth. Cancer
Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
NCCN Clinical Practice Guidelines in
Oncology. Prostate Cancer Journal V.3. 2010.
|
|
8
|
Tan WW: Novel agents and targets in
managing patients with metastatic prostate cancer. Cancer Control.
13:194–198. 2006.PubMed/NCBI
|
|
9
|
Zhu ML and Kyprianou N: Androgen receptor
and growth factor signaling cross-talk in prostate cancer cells.
Endocr Relat Cancer. 15:841–849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cinar B, De Benedetti A and Freeman MR:
Post-transcriptional regulation of the androgen receptor by
Mammalian target of rapamycin. Cancer Res. 65:2547–2553. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Chen SY, Ross KN and Balk SP:
Androgens induce prostate cancer cell proliferation through
mammalian target of rapamycin activation and post-transcriptional
increases in cyclin D proteins. Cancer Res. 66:7783–7792. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Mikhailova M, Bose S, Pan CX,
deVere White RW and Ghosh PM: Regulation of androgen receptor
transcriptional activity by rapamycin in prostate cancer cell
proliferation and survival. Oncogene. 27:7106–7117. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar
|
|
14
|
Bjornsti MA and Houghton PJ: The TOR
pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guertin DA and Sabatini DM: An expanding
role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kremer CL, Klein RR, Mendelson J, et al:
Expression of mTOR signaling pathway markers in prostate cancer
progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki H, Freije D, Nusskern DR, et al:
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple
metastatic prostate cancer tissues. Cancer Res. 58:204–209.
1998.PubMed/NCBI
|
|
18
|
Wang SI, Parsons R and Ittmann M:
Homozygous deletion of the PTEN tumor suppressor gene in a subset
of prostate adenocarcinomas. Clin Cancer Res. 4:811–815.
1998.PubMed/NCBI
|
|
19
|
McCall P, Witton CJ, Grimsley S, Nielsen
KV and Edwards J: Is PTEN loss associated with clinical outcome
measures in human prostate cancer? Br J Cancer. 99:1296–1301. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neshat MS, Mellinghoff IK, Tran C, et al:
Enhanced sensitivity of PTEN-deficient tumors to inhibition of
FRAP/mTOR. Proc Natl Acad Sci USA. 98:10314–10319. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mills GB, Lu Y and Kohn EC: Linking
molecular therapeutics to molecular diagnostics: inhibition of the
FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks
PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA.
98:10031–10033. 2001. View Article : Google Scholar
|
|
22
|
Podsypanina K, Lee RT, Politis C, et al:
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase
activity in PTEN+/− mice. Proc Natl Acad Sci USA.
98:10320–10325. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rivera VM, Squillace RM, Miller D, et al:
Ridaforolimus (AP23573, MK-8669), a potent mTOR inhibitor, has
broad antitumor activity and can be optimally administered using
intermittent dosing regimens. Mol Cancer Ther. 10:1059–1071. 2011.
View Article : Google Scholar
|
|
24
|
Colombo N, McMeekin S, Schwartz P, et al:
A phase II trial of the mTOR inhibitor AP23573 as a single agent in
advanced endometrial cancer. J Clin Oncol. 25(18S): 55162007.
|
|
25
|
Mutter GL: Pten, a protean tumor
suppressor. Am J Pathol. 158:1895–1898. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mutter GL, Lin MC, Fitzgerald JT, et al:
Altered PTEN expression as a diagnostic marker for the earliest
endometrial precancers. J Natl Cancer Inst. 92:924–930. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chow LM and Baker SJ: PTEN function in
normal and neoplastic growth. Cancer Lett. 241:184–196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Squillace RM, Miller D, Cookson M, et al:
Antitumor activity of ridaforolimus and potential cell cycle
determinants of sensitivity in sarcoma and endometrial cancer
models. Mol Cancer Ther. 10:1959–1968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Majumder PK, Febbo PG, Bikoff R, et al:
mTOR inhibition reverses Akt-dependent prostate intraepithelial
neoplasia through regulation of apoptotic and HIF-1-dependent
pathways. Nat Med. 10:594–601. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mousses S, Wagner U, Chen Y, et al:
Failure of hormone therapy in prostate cancer involves systematic
restoration of androgen responsive genes and activation of
rapamycin sensitive signaling. Oncogene. 20:6718–6723. 2001.
View Article : Google Scholar
|
|
31
|
Gao N, Zhang Z, Jiang BH and Shi X: Role
of PI3K/AKT/mTOR signaling in the cell cycle progression of human
prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang W, Zhu J, Efferson CL, et al:
Inhibition of tumor growth progression by antiandrogens and mTOR
inhibitor in a Pten-deficient mouse model of prostate cancer.
Cancer Res. 69:7466–7472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gray IC, Phillips SM, Lee SJ, Neoptolemos
JP, Weissenbach J and Spurr NK: Loss of the chromosomal region
10q23-25 in prostate cancer. Cancer Res. 55:4800–4803.
1995.PubMed/NCBI
|
|
35
|
Komiya A, Suzuki H, Ueda T, et al: Allelic
losses at loci on chromosome 10 are associated with metastasis and
progression of human prostate cancer. Genes Chromosomes Cancer.
17:245–253. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gray IC, Stewart LM, Phillips SM, et al:
Mutation and expression analysis of the putative prostate
tumour-suppressor gene PTEN. Br J Cancer. 78:1296–1300. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McMenamin ME, Soung P, Perera S, Kaplan I,
Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded
primary prostate cancer correlates with high Gleason score and
advanced stage. Cancer Res. 59:4291–4296. 1999.PubMed/NCBI
|
|
38
|
Burton JL, Oakley N and Anderson JB:
Recent advances in the histopathology and molecular biology of
prostate cancer. BJU Int. 85:87–94. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang S, Gao J, Lei Q, et al:
Prostate-specific deletion of the murine Pten tumor suppressor gene
leads to metastatic prostate cancer. Cancer Cell. 4:209–221. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao H, Ouyang X, Banach-Petrosky WA, Shen
MM and Abate-Shen C: Emergence of androgen independence at early
stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer
Res. 66:7929–7933. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Z, Trotman LC, Shaffer D, et al:
Crucial role of p53-dependent cellular senescence in suppression of
Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Di Cristofano A, De Acetis M, Koff A,
Cordon-Cardo C and Pandolfi PP: Pten and p27KIP1 cooperate in
prostate cancer tumor suppression in the mouse. Nat Genet.
27:222–224. 2001.PubMed/NCBI
|
|
43
|
Hellerstedt BA and Pienta KJ: The current
state of hormonal therapy for prostate cancer. CA Cancer J Clin.
52:154–179. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schayowitz A, Sabnis G, Njar VC and Brodie
AM: Synergistic effect of a novel antiandrogen, VN/124-1, and
signal transduction inhibitors in prostate cancer progression to
hormone independence in vitro. Mol Cancer Ther. 7:121–132. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Murillo H, Huang H, Schmidt LJ, Smith DI
and Tindall DJ: Role of PI3K signaling in survival and progression
of LNCaP prostate cancer cells to the androgen refractory state.
Endocrinology. 142:4795–4805. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chan S: Targeting the mammalian target of
rapamycin (mTOR): a new approach to treating cancer. Br J Cancer.
91:1420–1424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Thalmann GN, Anezinis PE, Chang SM, et al:
Androgen-independent cancer progression and bone metastasis in the
LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581.
1994.PubMed/NCBI
|
|
48
|
Thalmann GN, Sikes RA, Wu TT, et al: LNCaP
progression model of human prostate cancer: androgen-independence
and osseous metastasis. Prostate. 44:91–103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dehm SM and Tindall DJ: Ligand-independent
androgen receptor activity is activation function-2-independent and
resistant to antiandrogens in androgen refractory prostate cancer
cells. J Biol Chem. 281:27882–27893. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nash AF and Melezinek I: The role of
prostate specific antigen measurement in the detection and
management of prostate cancer. Endocr Relat Cancer. 7:37–51. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ryan CJ, Smith A, Lal P, et al: Persistent
prostate-specific antigen expression after neoadjuvant androgen
depletion: an early predictor of relapse or incomplete androgen
suppression. Urology. 68:834–839. 2006. View Article : Google Scholar
|
